Navigation Links
Trial seeks 'genetic fingerprint' for predicting drug effectiveness
Date:10/3/2007

CINCINNATIUniversity of Cincinnati (UC) physician-scientists believe identifying a genetic fingerprint could help predict which specific therapies will be most effective for patients with gastric cancer.

Syed Ahmad, MD, is leading a national, phase-2 trial to test the effectiveness of combined chemotherapy and radiation therapy given to patients with gastric cancer before surgery. His team will also collect biological samples in an attempt to obtain genetic data that could be used to formulate targeted therapies.

Previous studies have established that either chemotherapy or radiation therapy after surgery can improve patient survival compared with surgery alone. Overall survival rates, however, remain lowwith 20 to 30 percent of American patients surviving more than five years after treatment.

Everyone agrees that without surgery, gastric cancer in not curable, and numerous studies have shown a benefit to follow-up therapy with either chemotherapy or radiation therapy, says Ahmad, assistant professor of surgery at UC and principal investigator of the trial.

The problem is you cant give both radiation therapy and chemotherapy after surgeryits too toxic and patients cant tolerate it, he says. But you can give it before surgery when patients are healthiest.

This trial addresses what Ahmad calls the future of cancer therapy: targeted drug regimens, based on the characteristics of a patients specific tumor.

His goal is to identify a genetic fingerprint that could help predict whether patients will respond to therapy, and then identify drugs to address the specific molecular characteristics of that patients tumor.

Right now treatment is based on the assumption that site-based cancers are all the same, so every patient who has stage-3 gastric cancer will get the same chemotherapy drugs, Ahmad explains. But the reality is that every cancer has a different expression of hormones, growth factors and genetic factors that must be addressed individually.

The UC-led national team is looking for about 70 patients across the United States with up to stage-3 gastric cancer to participate in the trial.

Prior to surgery, all study participants will have a biopsy to set baseline standards for genetic testing to determine which patients have a complete response to the multi-treatment therapy. Participants will receive daily doses of the platinum-containing drug oxaliplatin (ox-AL-ih-plah-tin, marketed as Eloxatin) for six to eight weeks.

Approved by the Food and Drug Administration, oxaliplatin is currently used to treat advanced colorectal cancer. Studies have shown the drug has fewer toxicity complications compared with other therapies.

After six weeks of chemotherapy, the patient will get five consecutive days of three-dimensional, external-beam radiation therapy. Patients will be reevaluated two to three weeks after radiation to determine if they are eligible for surgery. Those who are suitable will have another tissue biopsy after surgery.

Researchers will compare pre- and post-surgery tissue samples to obtain the genetic data necessary to establish associations between molecular markers and drug resistance, with the goal of reducing toxicity associated with chemotherapeutic agents and improving patient survival.


'/>"/>

Contact: Amanda Harper
amanda.harper@uc.edu
513-558-4657
University of Cincinnati
Source:Eurekalert

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. NIAID Initiates Trial of Experimental Avian Flu Vaccine
3. International trial of two microbicides begins
4. Bird Brains Show How Trial and Error May Contribute to Learning
5. Use of PET can reduce, may eliminate more strenuous drug development trials with animals
6. HIV vaccine trial breaks ground for future research
7. Roche clinical trial registry and results database launched
8. NIAID begins clinical trial of West Nile virus vaccine
9. EuroVacc 02 HIV Vaccine Trial Begins
10. Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT
11. Compound might defeat African sleeping sickness, clinical trial beginning this month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... -- Hunova, the first robotic gym for the rehabilitation and functional motor sense ... Genoa, Italy . The first 30 robots will be available ... USA . The technology was developed and patented at the IIT ... Movendo Technology thanks to a 10 million euro investment from entrepreneur Sergio ... ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
Breaking Biology News(10 mins):
(Date:10/9/2017)... ... ... At its national board meeting in North Carolina, ARCS® Foundation ... Physics and Astronomy, has been selected for membership in ARCS Alumni Hall of ... Breakthrough Prize in Fundamental physics for the discovery of the accelerating expansion of the ...
(Date:10/7/2017)... Phoenix, Arizona (PRWEB) , ... ... ... than 15 years’ experience providing advanced instruments and applications consulting for microscopy ... the in-house expertise in application consulting, Nanoscience Analytical offers a broad range ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech Venture Network ... at their fourth annual Conference where founders, investors, innovative practitioners and collaborators are ... pitch competition showcasing early stage digital health and med tech companies. , This ...
(Date:10/5/2017)... ... , ... Understanding the microbiome, the millions of bacteria that live in our ... My Future, the newest exhibit on display at the University City Science Center’s Esther ... the lens of the gut microbiome. , Gut Love opens October 12, 2017, ...
Breaking Biology Technology: